Psoriasis - Pipeline Insight, 2024

Psoriasis - Pipeline Insight, 2024

DelveInsight’s, “Psoriasis – Pipeline Insight, 2024,” report provides comprehensive insights about 130+ companies and 130+ pipeline drugs in Psoriasis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Psoriasis Understanding

Psoriasis: Overview

Psoriasis is a chronic inflammatory skin disorder that is accompanied with various clinical manifestations and is caused due to the involvement of genetic, environmental, and immunological factors. It is a non-contagious dermatosis disease affecting almost 2% of the world population. The percentage of body affected by psoriasis can vary on an individual basis. It is possible to observe mild (<2%), moderate (2–10%), and severe (>10%) psoriasis in different people, however the most commonly witnessed psoriasis is chronic plaque psoriasis or psoriasis vulgaris. It is a chronic inflammatory skin disorder in which the dendritic cells, T lymphocytes, macrophages, neutrophils, and keratinocytes lead to skin lesions. Topical therapies are the standard of care for the treatment of mild to moderate form of the disease.

Psoriasis Types

• Plaque psoriasis
• Guttate psoriasis
• Flexural (inverse) psoriasis
• Erythroderma
• Generalised pustular psoriasis
• Palmoplantar pustulosis
• Psoriatic nail disease

Diagnosis

The diagnosis of psoriasis is found to be mostly on a clinical basis. The hallmarks observed in case of patients affected with psoriasis are well-demarcated, symmetric, and erythematous plaques with overlying silvery scale. Plaques can be seen typically in areas such as scalp, trunk, buttocks, and extremities but can also occur anywhere on the body. Patients can also depict nail involvement that can be present without concomitant plaques.

Treatment

A major population of patients can get benefitted from the topical therapies; this can also be initiated at the primary care level. If these particular topical agents do not provide an adequate response, the patients can be further referred to a dermatologist, at this particular point systemic therapy with topical adjuncts might be more beneficial. Presence of psoriatic arthritis involves systemic therapies in collaboration with a rheumatologist.

""Psoriasis - Pipeline Insight, 2021"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Psoriasis pipeline landscape is provided which includes the disease overview and Psoriasis treatment guidelines. The assessment part of the report embraces, in depth Psoriasis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Psoriasis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Psoriasis R&D. The therapies under development are focused on novel approaches to treat/improve Psoriasis.
• In November 2020, Biohaven Pharmaceutical collaborates with Weill Cornell Medicine, to initiate a clinical trial with a Biohaven CGRP-receptor antagonist for the treatment of plaque psoriasis. CGRP is a neuropeptide and believed to play an important role in the pathogenesis of inflammatory skin diseases such as psoriasis.

Psoriasis Emerging Drugs Chapters

This segment of the Psoriasis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Psoriasis Emerging Drugs

• Topical roflumilast: Arcutis Biotherapeutics

Topical roflumilast cream (ARQ-151) is a small molecule inhibitor of phosphodiesterase type 4 (PDE4), an intracellular enzyme that increases the production of proinflammatory mediators and decreases production of anti-inflammatory mediators, and has been implicated in a wide range of inflammatory diseases including psoriasis, eczema, and chronic obstructive pulmonary disease (COPD). The therapy is in Phase III clinical development for the treatment of Plaque Psoriasis.

• GSK2982772: GlaxoSmithKline

GSK2982772 is an ATP competitive receptor-interacting protein-1 (RIP1) kinase (RIPK1) inhibitor with the IC50 value of 16 nM. GSK2982772 potently binds to RIP1 with exquisite kinase specificity and has excellent activity in blocking many TNF-dependent cellular responses. RIP1 has emerged as an important upstream kinase that has been shown to regulate inflammation through both scaffolding and kinase specific functions. The molecule is in Phase I clinical development for the treatment of Psoriasis.

Further product details are provided in the report……..

Psoriasis: Therapeutic Assessment

This segment of the report provides insights about the different Psoriasis drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Psoriasis

There are approx. 130+ key companies which are developing the therapies for Psoriasis. The companies which have their Psoriasis drug candidates in the most advanced stage, i.e. Registered include, Biocad.

• Phases

DelveInsight’s report covers around 130+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Psoriasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravitreal
• Subretinal
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Psoriasis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Psoriasis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Psoriasis drugs.

Psoriasis Report Insights

• Psoriasis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Psoriasis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Psoriasis drugs?
• How many Psoriasis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Psoriasis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Psoriasis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Psoriasis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Mylan
• Biocad
• Bristol-Myers Squibb
• Celltrion
• Coherus BioSciences
• Janssen Pharmaceuticals
• Can-Fite Biopharma
• Arcutis Biotherapeutics
• Amgen
• Iltoo Pharma
• GlaxoSmithKline
• Galectin Therapeutics
• Evelo Biosciences
• Galderma
• BioMimetix JV
• Menlo Therapeutics Inc.
• Aristea Therapeutics
• UNION Therapeutics
• MetrioPharm
• Sienna Biopharmaceuticals

Key Products

• MYL-1401A
• BCD-057
• BMS-986165
• CT-P43
• CHS-1420
• Guselkumab
• Piclidenoson
• ARQ-154
• ABP 654
• Interleukin-2
• GSK2982772
• GR-MD-02
• EDP1815
• CD10367
• BMX-010
• Serlopitant
• RIST4721
• UNI-50001
• MP1032
• SNA-120